DK672788A - Rekombinant-dna-vektorer til direkte udtrykkelse af aktiveret humant protein c - Google Patents

Rekombinant-dna-vektorer til direkte udtrykkelse af aktiveret humant protein c

Info

Publication number
DK672788A
DK672788A DK672788A DK672788A DK672788A DK 672788 A DK672788 A DK 672788A DK 672788 A DK672788 A DK 672788A DK 672788 A DK672788 A DK 672788A DK 672788 A DK672788 A DK 672788A
Authority
DK
Denmark
Prior art keywords
humant
protein
activated
recombinant dna
direct expression
Prior art date
Application number
DK672788A
Other languages
English (en)
Other versions
DK672788D0 (da
Inventor
Nils Ulrik Bang
Hartmut Josef Ehrlich
Brian William Grinnell
Jr Standley Richard Jaskunas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK672788D0 publication Critical patent/DK672788D0/da
Publication of DK672788A publication Critical patent/DK672788A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
DK672788A 1987-12-04 1988-12-02 Rekombinant-dna-vektorer til direkte udtrykkelse af aktiveret humant protein c DK672788A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/129,027 US4992373A (en) 1987-12-04 1987-12-04 Vectors and compounds for direct expression of activated human protein C

Publications (2)

Publication Number Publication Date
DK672788D0 DK672788D0 (da) 1988-12-02
DK672788A true DK672788A (da) 1989-07-28

Family

ID=22438133

Family Applications (1)

Application Number Title Priority Date Filing Date
DK672788A DK672788A (da) 1987-12-04 1988-12-02 Rekombinant-dna-vektorer til direkte udtrykkelse af aktiveret humant protein c

Country Status (20)

Country Link
US (1) US4992373A (da)
EP (1) EP0319312B1 (da)
JP (1) JP2749083B2 (da)
KR (1) KR970009081B1 (da)
CN (1) CN1035527A (da)
AR (1) AR245217A1 (da)
AT (1) ATE96840T1 (da)
AU (1) AU610301B2 (da)
CA (1) CA1339938C (da)
DE (1) DE3885419T2 (da)
DK (1) DK672788A (da)
ES (1) ES2059538T3 (da)
HU (1) HU209587B (da)
IE (1) IE61627B1 (da)
IL (1) IL88559A (da)
MX (1) MX166847B (da)
NZ (1) NZ227177A (da)
PT (1) PT89135B (da)
RU (1) RU1830081C (da)
ZA (1) ZA889033B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6437298A (en) * 1987-08-04 1989-02-07 Hiroshi Okamoto Production of c-terminal amidated peptide
EP0485504B1 (en) * 1989-08-11 1993-12-01 Zymogenetics, Inc. Cell culture methods for producing activated protein c
JP3270462B2 (ja) * 1989-12-29 2002-04-02 ザイモジェネティクス,インコーポレイティド ハイブリッドプロテインc
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
EP0785273A1 (en) * 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
ATE211177T1 (de) * 1991-01-11 2002-01-15 American Nat Red Cross Expression von aktivem menschlichem protein c im milchdrüsengewebe transgener tiere
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US6262336B1 (en) 1991-01-11 2001-07-17 American Red Cross Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
US5464934A (en) * 1993-05-14 1995-11-07 Mallinckrodt Medical, Inc. Metal chelates as spacer compounds in biologically active peptides
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
US5698444A (en) * 1993-12-23 1997-12-16 Eli Lilly And Company Serotonin receptor protein and related nucleic acid compounds
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US5723755A (en) * 1995-05-16 1998-03-03 Francis E. Lefaivre Large scale production of human or animal proteins using plant bioreactors
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
US5905185A (en) * 1995-11-30 1999-05-18 Ppl Therapeutics Protein C production in non-human transgenic mammals
ZA983496B (en) * 1997-04-28 1999-10-25 Lilly Co Eli Methods for processing activated protein C.
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
BR9809932A (pt) * 1997-06-05 2000-08-01 Lilly Co Eli Métodos para tratamento de distúrbios trombóticos
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6103524A (en) * 1998-07-30 2000-08-15 Eli Lilly And Company Metabotropic glutamate receptor protein and nucleic acid
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CN1324244A (zh) 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
DE69930419T2 (de) 1998-11-13 2006-09-07 Eli Lilly And Co., Indianapolis Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE235915T1 (de) 1998-11-20 2003-04-15 Lilly Co Eli Behandlung von hämorrhagischem virusfieber mit protein c
BR9915572A (pt) 1998-11-23 2001-08-14 Lilly Co Eli Processo de tratamento de doença de célula falciforme e talassemia
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
CA2372907A1 (en) * 1999-04-30 2000-11-09 Andrew Darrow Zymogen activation system
US6420157B1 (en) * 1999-04-30 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Zymogen activation system
EP1237917A2 (en) * 1999-11-19 2002-09-11 Eli Lilly And Company Protein c derivatives
US6841371B2 (en) 2000-02-02 2005-01-11 Eli Lilly And Company Protein C derivatives
JP2003521938A (ja) 2000-02-11 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインc誘導体
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (en) 2000-05-24 2003-03-12 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
MXPA03003388A (es) * 2000-10-18 2005-03-07 Maxygen Aps Moleculas de proteina c o similares a las de proteina c activadas.
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
EP1453529A4 (en) 2001-09-19 2007-09-26 Oklahoma Med Res Found TREATMENT OF SEPSIS WITH TAFI
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインcによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
AU2006250889A1 (en) * 2005-05-24 2006-11-30 Avesthagen Limited A process comprising codon optimization for the production of recombinant activated human protein C for the treatment of sepsis
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
BRPI0613137A2 (pt) * 2005-06-24 2010-12-21 Drugrecure Aps administração em vias aéreas de proteìna c ativada em condições inflamatórias afetando o trato respiratório
EP2041338A4 (en) * 2006-06-09 2009-09-30 Univ British Columbia INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF RESULT IN SERIOUSLY SICK SUBJECTS
CA2712057A1 (en) * 2008-01-15 2009-07-23 The University Of British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
RU2469093C2 (ru) * 2008-12-19 2012-12-10 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
ES2629099T3 (es) 2008-12-19 2017-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Derivados de serin proteasa y usos en la prevención o el tratamiento de y trastornos de la coagulación sanguinea
EP2199387A1 (en) 2008-12-19 2010-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses for the prevention and/or the treatment of blood coagulation disorders
EP2539448B1 (en) * 2010-02-26 2016-12-14 The Children's Hospital of Philadelphia Protein c zymogen and methods of use thereof to prevent cancer metastases
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US11895994B2 (en) 2019-10-27 2024-02-13 Shanghai Raas Blood Products Co., Ltd. Humanized knock-in mouse expressing human Protein C
JPWO2023171719A1 (da) * 2022-03-08 2023-09-14

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4603105A (en) * 1982-05-27 1986-07-29 Kaplan Donald A Efficient screening methods for low probability variants
GB8327860D0 (en) * 1983-10-18 1983-11-16 Fujisawa Pharmaceutical Co Monoclonal antiprotein c antibody
US4617265A (en) * 1984-09-19 1986-10-14 Board Of Regents, University Of Texas System Colony blot assay for enterotoxigenic bacteria
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
CA1341228C (en) * 1985-06-27 2001-05-15 Mark J. Murray Expression of protein c
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
GB8728837D0 (en) * 1987-12-10 1988-01-27 Eaton Corp Semi-automatic mechanical transmission control and control and control method
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c

Also Published As

Publication number Publication date
AR245217A1 (es) 1993-12-30
RU1830081C (ru) 1993-07-23
IE61627B1 (en) 1994-11-16
AU2650988A (en) 1989-06-08
EP0319312A3 (en) 1990-09-19
IL88559A0 (en) 1989-07-31
CA1339938C (en) 1998-07-07
HU209587B (en) 1994-08-29
KR970009081B1 (en) 1997-06-05
IE883612L (en) 1989-06-04
EP0319312A2 (en) 1989-06-07
US4992373A (en) 1991-02-12
CN1035527A (zh) 1989-09-13
AU610301B2 (en) 1991-05-16
HUT50497A (en) 1990-02-28
JPH022372A (ja) 1990-01-08
MX166847B (es) 1993-02-09
ES2059538T3 (es) 1994-11-16
PT89135A (pt) 1989-12-29
DE3885419T2 (de) 1994-03-31
DE3885419D1 (de) 1993-12-09
JP2749083B2 (ja) 1998-05-13
ATE96840T1 (de) 1993-11-15
ZA889033B (en) 1990-08-29
DK672788D0 (da) 1988-12-02
KR890010199A (ko) 1989-08-07
IL88559A (en) 1994-02-27
NZ227177A (en) 1990-07-26
EP0319312B1 (en) 1993-11-03
PT89135B (pt) 1994-04-29

Similar Documents

Publication Publication Date Title
DK672788D0 (da) Rekombinant-dna-vektorer til direkte udtrykkelse af aktiveret humant protein c
DK230683D0 (da) Rekombinante dna-klonende vektorer til udtrykkelse af endogent protein
FR2621487B1 (fr) Virus avipox recombinant
FI884924A7 (fi) Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
DK538485A (da) Rekombinante dna-molekyler
FI855141A7 (fi) Rekombinantti-DNA-vektoreita, jotka kykenevät ilmaisemaan apoaequoriinia.
NO863902D0 (no) Fremgangsmaate ved opprensing av proteiner.
DK216589A (da) Dna sekvenser, rekombinante dna molekyler samt fremgangsmaader til fresmtilling af oploeselige t4-proteiner
FI883708L (fi) Menetelmä emäksisten proteiinien eristämiseksi proteiiniseoksista, jotka sisältävät tällaisia emäksisiä proteiineja
DE3685626D1 (de) Sequenzierung von peptiden.
DK517787D0 (da) Lymphokinbeslaegtede peptider
DK275788D0 (da) Protein
DK41590A (da) Forbedrede protein c-molekyler samt fremgangsmaade til fremstilling og aktivering af samme
KR950702242A (ko) 사포린 함유 단백질의 재조합 생산방법(Recombinant production of saporin-containing proteins)
DK549688A (da) Fremstilling af peptider
DK723488D0 (da) Fremgangsmaade til rekombinant udtrykkelse af zymogene former af humant protein c samt vektorer, dna-forbindelser og transformanter til brug ved fremgangsmaaden
FI941749L (fi) Rekombinantti-Borrelia -proteiinien valmistus
DK675389A (da) Terapeutiske praeparater til forebyggelse af fibrinaflejringer
DK209288D0 (da) Fraskillelse af aktiveret humant protein c
DK345087D0 (da) Protein
DK623188A (da) Fremgangsmaade til inkubation af rekombinante proteinekspressionsceller
DE3880226D1 (de) Derivate von calcitonin verwandten gen-peptiden.
DK0401657T3 (da) Fremgangsmåde til C-terminal modificering af proteiner
FI902151A7 (fi) Yhdistelmä-DNA-fuusioproteiineja hormonierityksen muuttamiseksi
FI892769A7 (fi) Menetelmä yhdistelmä-DNA:n inaktivoimiseksi

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment